These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

239 related articles for article (PubMed ID: 18027228)

  • 61. Sequential boundaries approach in clinical trials with unequal allocation ratios.
    Jafari P; Ayatollahi SM; Behboodian J
    BMC Med Res Methodol; 2006 Jan; 6():1. PubMed ID: 16412232
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Issues in the use of adaptive clinical trial designs.
    Emerson SS
    Stat Med; 2006 Oct; 25(19):3270-96; discussion 3302-4, 3320-5, 3326-47. PubMed ID: 16906553
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Mid-course sample size modification in clinical trials based on the observed treatment effect.
    Jennison C; Turnbull BW
    Stat Med; 2003 Mar; 22(6):971-93. PubMed ID: 12627413
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Interim analyses in 2 x 2 crossover trials.
    Cook RJ
    Biometrics; 1995 Sep; 51(3):932-45. PubMed ID: 7548709
    [TBL] [Abstract][Full Text] [Related]  

  • 65. On adaptive error spending approach for group sequential trials with random information levels.
    Liu Q; Lim P; Nuamah I; Li Y
    J Biopharm Stat; 2012; 22(4):687-99. PubMed ID: 22651109
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Estimation in flexible two stage designs.
    Brannath W; König F; Bauer P
    Stat Med; 2006 Oct; 25(19):3366-81. PubMed ID: 16220489
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Increasing the sample size at interim for a two-sample experiment without Type I error inflation.
    Dunnigan K; King DW
    Pharm Stat; 2010; 9(4):280-7. PubMed ID: 19764040
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Test for the consistency of noninferiority from multiple clinical trials.
    Yan X; Wang MC; Su X
    J Biopharm Stat; 2007; 17(2):265-78. PubMed ID: 17365223
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Tests for inter-subject and total variabilities under crossover designs.
    Lee Y; Shao J; Chow SC; Wang H
    J Biopharm Stat; 2002 Nov; 12(4):503-34. PubMed ID: 12477072
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Efficient ways exist to obtain the optimal sample size in clinical trials in rare diseases.
    van der Lee JH; Wesseling J; Tanck MW; Offringa M
    J Clin Epidemiol; 2008 Apr; 61(4):324-30. PubMed ID: 18313556
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Population enrichment designs: case study of a large multinational trial.
    Mehta CR; Gao P
    J Biopharm Stat; 2011 Jul; 21(4):831-45. PubMed ID: 21516572
    [TBL] [Abstract][Full Text] [Related]  

  • 72. An algorithm for the design of group sequential triangular tests for single-arm clinical trials with a binary endpoint.
    McWilliams TP
    Stat Med; 2010 Nov; 29(27):2794-801. PubMed ID: 20860065
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Biomarker-adaptive threshold design: a procedure for evaluating treatment with possible biomarker-defined subset effect.
    Jiang W; Freidlin B; Simon R
    J Natl Cancer Inst; 2007 Jul; 99(13):1036-43. PubMed ID: 17596577
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Two-stage design of clinical trials involving recurrent events.
    Cook RJ; Bergeron PJ; Boher JM; Liu Y
    Stat Med; 2009 Sep; 28(21):2617-38. PubMed ID: 19579215
    [TBL] [Abstract][Full Text] [Related]  

  • 75. A free gift: an adaptive strategy in a single-arm trial using an exact test through the binomial distribution.
    Wang J
    J Biopharm Stat; 2012; 22(6):1127-36. PubMed ID: 23075012
    [TBL] [Abstract][Full Text] [Related]  

  • 76. A SAS macro for sample size adjustment and randomization test for internal pilot study.
    Wang S; Xia J; Yu L; Li C; Xu L
    Comput Methods Programs Biomed; 2008 Apr; 90(1):66-88. PubMed ID: 18192069
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Statistical analysis for two-stage seamless design with different study endpoints.
    Chow SC; Lu Q; Tse SK
    J Biopharm Stat; 2007; 17(6):1163-76. PubMed ID: 18027223
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Sample size determination using an interim analysis.
    Bristol DR
    J Biopharm Stat; 1993 Sep; 3(2):159-66. PubMed ID: 8220401
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Optimizing trial design in pharmacogenetics research: comparing a fixed parallel group, group sequential, and adaptive selection design on sample size requirements.
    Boessen R; van der Baan F; Groenwold R; Egberts A; Klungel O; Grobbee D; Knol M; Roes K
    Pharm Stat; 2013; 12(6):366-74. PubMed ID: 24214896
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Interim analyses and early termination of clinical trials.
    Choi SC
    J Biopharm Stat; 1997 Nov; 7(4):533-43. PubMed ID: 9358327
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.